focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for posting it from the Telegram group ( I'm not a member) all very encouraging for the delivery of some very good news.
0 0 0
Eric confirmed in his August/September interview that Genflow are in negotiation for two non-dilutive research grants which would provide funds for 80% of their R & D for an additional 3 years, fully cashed well into 2026, and so confrmation news in the pipeline along with an update on their Werner Syndrome accelerated clinical plans highly likely. Gl :-)
Evening Money.
I can’t take the credit for that. Someone else found it.
All very promising. Hopefully now the news can drop.
GLA
Nice on Northeast, a great find and thanks for posting. Excitement building. Gl :-)
The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from the relatively low operating costs and from substantial (non diluting) grants that support its research and development that are available from Belgium’s Wallonia region.
In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.
Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The Company believes that positive clinical data will be the source of significant value creation through, potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the path to a specific aging indication.
Partners:
University of Liège | Free University of Brussels - LME | ULG -CORD | CER Group | Revatis | GenFlow Biosciences | QUALITY ASSISTANCE S.A. | UNIVERCELLS | Kaneka Belgium NV | Eurogentec | UCB | BIOPHARMA | Henogen S.A. | UCLouvain - Catholic University of Leuven (TRAIL) - @PILAB | UCL - IMCN/BSMA | UCL -IREC | ULB-BCTL | LiveDrop | salamanderU | PDC*line Pharma | Orgenesis Belgium | DNAlytics | CELYNTRA THERAPEUTICS | OncoDNA | PharmaLex | UCL -LFEM | ULB -CMMI | UMONS - CMMI | XOMEXBIO | Vésale Bioscience | NOVADIP Biosciences S.A. | EXOBIOLOGIC | CYLIX GROUP |
just been posted on telegram! genf mentioned
*************c/1547827892/1748
as part of the wallonia recovery plan, the walloon government is launching an innovation partnership dedicated to atmps (innovative therapy drugs) with a budget of €81 million - 60% public money and 40% private business funds - over 3 years, in collaboration with the biowin cluster - the health cluster of wallonia and the public service of wallonia.
🔬 the partnership involves 26 partners and aims to maintain leadership and strengthen the sector in wallonia by establishing new collaborations between academic partners, a research centre and companies of all sizes.
💊 advanced therapy drugs are new generation biomedicines aimed at meeting unmet medical needs (breast and colorectal cancer, solid tumours, liver fibrosis, central nervous system pathologies...). they represent one of the most innovative and promising revolutions in modern medicine.
👩🏻🔬👨🏼🔬it is estimated that more than 470 direct and 1,200 indirect jobs will be created in the next five years. the atmp sector in wallonia already represents 6,000 direct and indirect jobs.
the atmp pit is a unique opportunity for the development and growth of a sector of importance for the future of wallonia.
Ps the Estee Lauder connection is very interesting and potentially very exciting considering Genflow's GF-3001 for Werner Syndrome ( premature ageing disease ) is a Topical delivery of Sirt6 directly to the skin, and so endless opportunities and potential in all aspects of age reversal. Gla :-)
Cheers Northeast, anytime now and hopefully the start of a great year ahead for all invested as positive newsflow is delivered, and yes indeed Porter, any association with Estee Lauder's longevity aspirations involving Sirtuin R&D can only be a good thing for Genflow going forward. C'mon Eric , ready when you are!!! ;-)
It is reassuring to see giants like Estée Lauder working on innovative skincare with Genflow’s own advisors and collaborative partners.
Not long now until the world economic forum meets, where it is expected longevity will be amongst the key topics under discussion, with a better focus globally on the work that companies like Genflow are achieving.
Evening Money!
Great posts as always. As the long wait here continues, I’m sure news will land any day now. For certain. Funding grants and new projects!
GL
Interestingly enough, Estee Lauder's new longevity product is the patented Sirtivity-LP technology, and appear to be investing heavily into the longevity space. Gla ;-)
From January 2024, the Estée Lauder Longevity Collective will serve as a brand advisory board, bringing new insights, research findings and resources to inform the brand’s ongoing approach to skin longevity research.
Collective members include Dr Nadine Pernodet, the brand’s Senior Vice President, Bioscience, Global R&D; long-term Estée Lauder partner Dr Danica Chen, Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California Berkeley; and Serena Liang Jing, a ‘New Map of Life’ Fellow at the Stanford Center on Longevity.
Experts from the Buck Institute for Research on Aging, the Center of Aging Research & Clinical Care at Weill Cornell Medicine, and the Stanford University School of Medicine will also be involved.
Next month will further see Estée Lauder launch Re-Nutriv Ultimate Diamond Transformative Brilliance Soft Crème.
The new sku is made with the brand’s patented Sirtivity-LP technology, which reveals visible age reversal starting at 14 days of use.
It is said to be the result of two decades of Estée Lauder’s study into the role of sirtuins – commonly known as ‘longevity proteins’ – in skin.
“The Estée Lauder brand has always been at the forefront of skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
https://cosmeticsbusiness.com/est%C3%A9e-lauder-targets-age-reversal-with-stanford-center
The Future Is Bright
To a certain extent, the things you can do now to prevent premature aging is to live a healthy lifestyle that limits stress, follow a healthy diet, exercise regularly, and so on.
Fortunately, the future’s looking bright with medical biotechnological advancements.
Genflow Biosciences works with major anti-aging research centers across the globe and believes that the SIRT6 gene is a master regulator of managing healthy aging and the potential therapeutic target preserve function.
These discoveries are in pursuit of finding disruptive anti-aging drugs. In fact, clinical testing is starting to happen, albeit in the infancy stages, making way for potentially transformative medicines.
hTtps://genflowbio.com/premature-aging/
GenFlow Biosciences
1,399 followers
1h
At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF), we're passionate about unveiling the mysteries of aging. Our latest article dives deep into premature aging, offering valuable insights on how your lifestyle choices and genetic factors play a crucial role. Learn about the impacts on various body systems and get expert tips for staying youthful and healthy.
Read it here: htTps://loom.ly/565AscQ
#longevity #aging #healthspan
GenFlow Biosciences
1,399 followers
21h
In Sardinia, GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) is initiating a pioneering human proof-of-concept Phase I/II trial for Werner Syndrome, which serves as a model for studying premature aging in humans. Investigating its causes offers valuable insights into the aging process and may lead to strategies that enhance overall health and longevity.
Learn more about Werner here:
htTps://loom.ly/RcDWpwk #Werner #longevity #aging #healthspan
The date in the URL link below is November 2023, no doubt following the news of the appointment of the Joint Broker, and as good news could drop at anytime , it looks like there's going to be plenty of UPward momentum in sp in anticipation...Excitement building!!! Gl ;-)
When was that presentation released MM ?
Genflow Corporate Power Point Presentation
hTtps://genflowbio.com/wp-content/uploads/2023/11/GENF.corporate.US_.v1sm.pdf
The FDA are moving closer to award full approval ( trial result dependent ) for a longeity drug for dogs, so highly significant for Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs) and every chance we could get confirmation of the planned Pivotal trial anti-aging for dogs and an announcement of a JV Veterinary partner. Gla ;-)
29/11/3
A San Francisco-based biotechnology firm is on a mission to keep your best friend around a little longer.
Loyal is spearheading the development of an experimental drug geared toward extending the lifespan of large-breed dogs by a minimum of one year. On Tuesday, it secured conditional approval for its medication from the U.S. Food and Drug Administration.
The landmark approval clears the way for more extensive clinical trials. It also marks the first time the agency has endorsed a longevity drug.
hTtps://www.sfchronicle.com/sf/article/s-f-startup-wants-help-dogs-live-longer-got-fda-18522309.php
I got a feeling we will all be reading this, jam tomorrow mid 2024
Time they were putting some meat on the bone
Looks like UK Biotech is hot hot hot this year and Genflow's tiny market cap looks extremely attractive commensurate to near term news and exciting prospects and potential going forward, in run up to human trials 2025!!! Gla :-)
Great rise, but this is nothing compared to what is to come!
GLA
Looking good and strong with news expected soon, which could add significant value. Gla holders :-)
Good to see a company so on point with its social media munch. I enjoy watching their LinkedIn updates, as well as seeing the calibre of industry experts who like their posts, affirming that Genf are seen as fellow industry leaders in the field of longevity.
I was thinking more about the relevance with SIRT6 and food. We spend a fortune every year buying produce because it says organically reared. What would people pay for meat such as cow and chickens, if they’re reared on SIRT6 nutrients, as we all know we are what we eat and surely consumers would be happy to pay a premium for food enrichment that could prolong a healthy lifespan?
GenFlow Biosciences
1,386 followers
13h
Investing in GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) offers a unique opportunity to support pioneering work in the longevity field. Our company focuses on developing novel therapeutics that target the aging process, including our lead compound GF-1002, which is based on a centenarian variant of the SIRT6 gene. This innovative approach aims to extend both healthspan and lifespan, addressing the global challenge of aging and its associated health and economic impacts.
Learn more here: hTtps://loom.ly/MeQymHs
#GENF #longevity #healthspan #SIRT6
Agree munch. The pharma market is off to a hot start for 2024, and the team have so much to showcase. The company has been operating under radar, but things certainly look set to change, especially as more and more people become obsessed with the maintenance of good health, as our population gets older and older.